NovaBay Pharmaceuticals, Inc. (NBY) Release: Research Breakthrough For Deadly Flesh-Eating Disease Reported In The Journal Cell Highlights Importance Of Neutralization Of Toxins Associated With Flesh-Eating Bacteria
1/28/2014 9:11:23 AM
EMERYVILLE, Calif., Jan. 28, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY): In the latest issue of the journal Cell, scientists at the Hebrew University of Jerusalem's Faculty of Medicine showed that Streptococcus pyogenes, an ordinarily benign to mildly infectious bacteria, sometimes begins to produce bacterial toxins when it gets under the skin. Those toxins, in turn, cause a defensive stress response in neighboring human cells that triggers the bacteria to ramp up toxin production. Those toxins then rapidly destroy tissue and threaten the lives of patients. As many as 25% of victims die, even after being treated with antibiotics—adding up to an estimated 500,000 deaths and severe injuries worldwide each year, according to the Hebrew University of Jerusalem researchers. Many more victims may require amputations of an arm or a leg to save their lives.
Help employers find you! Check out all the jobs and post your resume.
comments powered by